معرفی
Dr. Errol Marliss serves as a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site, where he is affiliated with the Metabolic Disorders and Complications Program within the Centre for Translational Biology. He holds a professorship in the Department of Medicine at McGill University's Faculty of Medicine and Health Sciences, and maintains clinical connections through the Department of Family Medicine, Division of Secondary Care at the MUHC.
Dr. Marliss's research focuses on metabolic alterations in type 2 diabetes and obesity, with particular emphasis on protein metabolism. His work has demonstrated that insulin resistance affects both glucose metabolism and protein anabolism, and that increasing protein (amino acid) supply can overcome this resistance. His recent fMRI studies have revealed that brain activity in cognitive control regions, rather than hormones controlling energy balance, plays a critical role in weight loss. Currently, his team is conducting deep metabolic phenotyping in a multi-omic study examining the heterogeneity of type 2 diabetes.
His extensive publication record spans five decades, with recent work focusing on neurocognitive aspects of weight loss, insulin resistance mechanisms, and protein metabolism in diabetes. His research bridges clinical observations with molecular mechanisms, contributing significantly to our understanding of metabolic disorders. Dr. Marliss has pioneered investigations into the interplay between protein metabolism and insulin resistance, demonstrating that protein anabolism resistance accompanies glucose metabolism resistance in prediabetic states.
Dr. Marliss has been instrumental in advancing our understanding of the complex relationships between nutrition, metabolism, and diabetes. His work on protein metabolism in insulin resistance has opened new avenues for therapeutic interventions. His current multi-omic study of type 2 diabetes heterogeneity promises to provide deeper insights into personalized treatment approaches for this complex condition, potentially leading to more targeted therapies based on individual metabolic profiles.
